Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Free Cash Flow (2021 - 2026)

Nuvectis Pharma has reported Free Cash Flow over the past 6 years, most recently at -$6.5 million for Q1 2026.

  • Quarterly results put Free Cash Flow at -$6.5 million for Q1 2026, down 55.99% from a year ago — trailing twelve months through Mar 2026 was -$18.3 million (down 52.08% YoY), and the annual figure for FY2025 was -$16.0 million, down 30.72%.
  • Free Cash Flow reached -$6.5 million in Q1 2026 per NVCT's latest filing, down from -$4.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$2.4 million in Q3 2024 and bottomed at -$6.5 million in Q1 2026.
  • Median Free Cash Flow over the past 5 years was -$3.8 million (2023), compared with a mean of -$3.8 million.
  • The largest annual shift saw Free Cash Flow crashed 229.52% in 2022 before it skyrocketed 35.97% in 2024.
  • Over 5 years, Free Cash Flow stood at -$3.5 million in 2022, then fell by 9.5% to -$3.8 million in 2023, then soared by 35.97% to -$2.5 million in 2024, then tumbled by 61.22% to -$4.0 million in 2025, then plummeted by 63.84% to -$6.5 million in 2026.
  • Business Quant data shows Free Cash Flow for NVCT at -$6.5 million in Q1 2026, -$4.0 million in Q4 2025, and -$4.5 million in Q3 2025.